{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:47:55Z","timestamp":1784198875273,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gynecologic oncologists should be aware of the option of conception through IVF\/PGT-M for families with high BRCA related morbidity or mortality. Our objective was to investigate the cost-effectiveness of preimplantation genetic testing for selection and transfer of BRCA negative embryo in BRCA mutation carriers compared to natural conception.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cost-effectiveness of two strategies, conception through IVF\/PGT-M and BRCA negative embryo transfer versus natural conception with a 50% chance of BRCA positive newborn for BRCA mutation carriers was compared using a Markovian process decision analysis model. Costs of the two strategies were compared using quality adjusted life years (QALYs\u2019). All costs were discounted at 3%. Incremental cost effectiveness ratio (ICER) compared to willingness to pay threshold was used for cost-effectiveness analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>IVF\/ PGT-M is cost-effective with an ICER of 150,219 new Israeli Shekels, per QALY gained (equivalent to 44,480 USD), at a 3% discount rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IVF\/ PGT-M and BRCA negative embryo transfer compared to natural conception among BRCA positive parents is cost effective and may be offered for selected couples with high BRCA mutation related morbidity or mortality. Our results could impact decisions regarding conception among BRCA positive couples and health care providers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12958-021-00827-9","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T03:35:49Z","timestamp":1633836949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7987-404X","authenticated-orcid":false,"given":"Nadav","family":"Michaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Leshno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoni","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Safra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Peleg-Hasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Laskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Grisaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"827_CR1","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1056\/NEJMra012284","volume":"348","author":"R Wooster","year":"2003","unstructured":"Wooster R, Weber BL. Breast and ovarian cancer. Guttmacher AE, Collins FS, editors. N Engl J Med. 2003;348:2339\u201347.","journal-title":"N Engl J Med"},{"key":"827_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/humrep\/deg110","volume":"18","author":"F Shenfield","year":"2003","unstructured":"Shenfield F, Pennings G, Devroey P, Sureau C, Tarlatzis B, Cohen J, et al. Taskforce 5: Preimplantation genetic diagnosis. Hum Reprod. 2003;18:649\u201351.","journal-title":"Hum Reprod"},{"key":"827_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.fertnstert.2017.12.004","volume":"109","author":"H Daum","year":"2018","unstructured":"Daum H, Peretz T, Laufer N. BRCA mutations and reproduction. Fertil Steril. 2018;109:33\u20138.","journal-title":"Fertil Steril"},{"key":"827_CR4","doi-asserted-by":"publisher","first-page":"578.e1","DOI":"10.1016\/j.ajog.2017.06.038","volume":"217","author":"R Manchanda","year":"2017","unstructured":"Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans DG, et al. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. Am J Obstet Gynecol. 2017;217:578.e1\u2013578.e12.","journal-title":"Am J Obstet Gynecol"},{"key":"827_CR5","first-page":"1","volume":"107","author":"R Manchanda","year":"2015","unstructured":"Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, et al. Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the ashkenazi-jewish community: a randomized controlled trial. J Natl Cancer Inst. 2015;107:1\u201311.","journal-title":"J Natl Cancer Inst"},{"key":"827_CR6","doi-asserted-by":"crossref","unstructured":"Michaan N, Leshno M, Safra T, Sonnenblick A, Laskov I, Grisaru D. Cost effectiveness of whole population BRCA genetic screening for cancer prevention in Israel.\u00a0Cancer Prev Res (Phila). 2021;14(4):455\u201362.","DOI":"10.1158\/1940-6207.CAPR-20-0411"},{"key":"827_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/14647273.2017.1336259","volume":"21","author":"A Sharpe","year":"2018","unstructured":"Sharpe A, Avery P, Choudhary M. Reproductive outcome following pre-implantation genetic diagnosis (PGD) in the UK. Hum Fertil. 2018;21:120\u20137.","journal-title":"Hum Fertil"},{"key":"827_CR8","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/humrep\/dex265","volume":"32","author":"M De Rycke","year":"2017","unstructured":"De Rycke M, Goossens V, Kokkali G, Meijer-Hoogeveen M, Coonen E, Moutou C. ESHRE PGD consortium data collection XIV-XV: cycles from January 2011 to December 2012 with pregnancy follow-up to October 2013. Hum Reprod. 2017;32:1974\u201394.","journal-title":"Hum Reprod"},{"key":"827_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.fertnstert.2018.04.003","volume":"109","author":"J Daar","year":"2018","unstructured":"Daar J, Benward J, Collins L, Davis J, Davis O, Francis L, et al. Use of preimplantation genetic testing for monogenic defects (PGT-M) for adult-onset conditions: an ethics committee opinion. Fertil Steril. 2018;109:989\u201392.","journal-title":"Fertil Steril"},{"key":"827_CR10","unstructured":"NCCN clinical practice guidlines in oncology. Genetic\/Familial High Risk Assessment: Breast, Ovarian and Pancreatic [Internet]. 2020 Version 2.2021 - Novemb. [cited 2020 Jul 4]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf"},{"key":"827_CR11","unstructured":"Department of Health U, Services Centers for Disease Control H. 2016 Assisted Reproductive Technology National Summary Report [Internet] 2016. Available from: https:\/\/www.cdc.gov\/art\/reports\/"},{"key":"827_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.fertnstert.2015.10.018","volume":"105","author":"J Chang","year":"2016","unstructured":"Chang J, Boulet SL, Jeng G, Flowers L, Kissin DM. Outcomes of in vitro fertilization with preimplantation genetic diagnosis: an analysis of the United States assisted reproductive technology surveillance data, 2011\u20132012. Fertil Steril. 2016;105:394\u2013400.","journal-title":"Fertil Steril"},{"key":"827_CR13","unstructured":"Ovarian Cancer - Cancer Stat Facts [Internet]. [cited 2019 Dec 14]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html"},{"key":"827_CR14","unstructured":"Female Breast Cancer - Cancer Stat Facts [Internet]. [cited 2019 Dec 14]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"},{"key":"827_CR15","unstructured":"Israel - OECD Data [Internet]. [cited 2020 Oct 30]. Available from: https:\/\/data.oecd.org\/israel.htm"},{"key":"827_CR16","doi-asserted-by":"publisher","first-page":"6677","DOI":"10.1016\/j.vaccine.2007.07.018","volume":"25","author":"GM Ginsberg","year":"2007","unstructured":"Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J. Cost-utility analysis of vaccination against HPV in Israel. Vaccine. 2007;25:6677\u201391.","journal-title":"Vaccine."},{"key":"827_CR17","first-page":"1059","volume":"60","author":"E Levy-Lahad","year":"1997","unstructured":"Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997;60:1059\u201367 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9150153%0Ahttp:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=PMC1712434.","journal-title":"Am J Hum Genet"},{"key":"827_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/humrep\/dez203","volume":"35","author":"JH Lipton","year":"2020","unstructured":"Lipton JH, Zargar M, Warner E, Greenblatt EE, Lee E, Chan KKW, et al. Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1\/2 mutations. Hum Reprod. 2020;35:434\u201345.","journal-title":"Hum Reprod"},{"key":"827_CR19","doi-asserted-by":"crossref","unstructured":"Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations [internet].\u00a0Pharmacoeconomics. 2018;36(7):745\u201358.","DOI":"10.1007\/s40273-018-0672-z"},{"key":"827_CR20","doi-asserted-by":"crossref","unstructured":"Kram V, Peretz T, Sagi M. Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing.\u00a0Fam Cancer. 2006;5(4):327\u201335.","DOI":"10.1007\/s10689-006-0002-z"},{"key":"827_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cge.12149","volume":"85","author":"Y Laitman","year":"2014","unstructured":"Laitman Y, Vaisman Y, Feldman D, Helpman L, Gitly M, Paluch Shimon S, et al. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. Clin Genet. 2014;85:68\u201371 [cited 2019 Sep 2]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23517234.","journal-title":"Clin Genet"},{"key":"827_CR22","doi-asserted-by":"crossref","unstructured":"Heemskerk-Gerritsen BAM, Seynaeve C, Van Asperen CJ, Ausems MGEM, Coll\u00e9e JM, Van Doorn HC, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction.\u00a0J Natl Cancer Inst. 2015;107(5):djv033.","DOI":"10.1093\/jnci\/djv033"},{"key":"827_CR23","doi-asserted-by":"crossref","unstructured":"Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers.\u00a0J Natl Cancer Inst. 2017:109.","DOI":"10.1093\/jnci\/djw177"},{"key":"827_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jnci\/djy182","volume":"111","author":"MB Terry","year":"2019","unstructured":"Terry MB, Daly MB, Phillips KA, Ma X, Zeinomar N, Leoce N, et al. Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk. J Natl Cancer Inst. 2019;111:331\u20134 Oxford University Press; [cited 2020 Sep 20]. Available from: \/pmc\/articles\/PMC6410936\/?report=abstract.","journal-title":"J Natl Cancer Inst"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00827-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-021-00827-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00827-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T03:36:05Z","timestamp":1633836965000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-021-00827-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1186\/s12958-021-00827-9","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"After consultation with our local institutional review board of the Tel-Aviv Sourasky medical Center, as this work is a theoretical, mathematical model, not involving any human or animal subjects in any form, it was exempt from the need of IRB approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}